CT1195E CAR-T in R/R B-Cell Neoplasms

Phase 1, open-label, single-arm trial of CT1195E in B-cell non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Severity and incidence of Dose-Limiting Toxicities, Treatment-Related Adverse Events, and Adverse Events of Special Interest at 12 months and Maximum Tolerated Dose or dose range at 28 days. Planned start Nov 2025; status: not yet recruiting.